Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathiesMarie Scully, Samuel J. Machin, Beverley J. Hunt et al.|British Journal of Haematology|2012Cited by 861
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpuraMarie Scully, Samuel J. Machin, Vickie McDonald et al.|Blood|2011Cited by 420
Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical featuresMarie Scully, Samuel J. Machin, Helen Yarranton et al.|British Journal of Haematology|2008Cited by 376
Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS‐13Marie Scully, Samuel J. Machin, Hannah Cohen et al.|British Journal of Haematology|2006Cited by 267
Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapseJP Westwood, Marie Scully, Henry Goodwin Webster et al.|Journal of Thrombosis and Haemostasis|2012Cited by 175